Diseases of poverty pose an urgent health problem. Biotechnology can provide a critical piece of the solution.
In Africa, one child dies of malaria every 30 seconds. Tuberculosis claims nearly 2 million lives a year, most of them in Sub-Saharan Africa and Southeast Asia. Globally, hundreds of millions of lives are threatened by parasites and other infectious agents.
Today, biopharmaceutical companies invent most of the new medicines for cancer, cardiovascular disease, or diabetes. But these are diseases for which there is a commercial return for the investment. Can biotech innovators play the same pivotal role for neglected diseases?
We believe they can. We have investigated the Neglected Disease Pipeline and created a library of reports that encompass our extensive research on global health issues, the biopharmaceutical industry, and research and development (R&D) for new medicines. Through WIPO Re:Search, we help facilitate new partnerships between scientists that conduct research on neglected tropical diseases, malaria, and tuberculosis, and product developers that have come together to make their intellectual property and associated expertise available for the development of new global health solutions. We believe that by applying developed world technologies to neglected diseases, biotechnology can have a significant impact on the health of people in developing countries.